BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vyvgart (Efgartigimod Alfa) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vyvgart (Efgartigimod Alfa)\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06221501-7534@assetmemo.bio
DTSTAMP:20261121T005619Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Vyvgart (Efgartigimod Alfa): Phase 2 readout est. (NCT06221501)
DESCRIPTION:Vyvgart (Efgartigimod Alfa)\, phase 2\, Myasthenia Gravis.\nStu
 dy: Perioperative Efgartigimod for Thymoma and Myasthenia Gravis\nEstimate
 d primary completion: 30 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/efgartigimod-alfa#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06221501
URL:https://assetmemo.bio/drug/efgartigimod-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806916-7534@assetmemo.bio
DTSTAMP:20261121T005619Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Vyvgart (Efgartigimod Alfa): Phase 2 readout est. (NCT07806916)
DESCRIPTION:Vyvgart (Efgartigimod Alfa)\, phase 2.\nStudy: Efficacy and Saf
 ety of Efgartigimod in the Treatment of Guillain-Barré Syndrome(GREAT)\nE
 stimated primary completion: June 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/efgartigimod-alfa#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07806916
URL:https://assetmemo.bio/drug/efgartigimod-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07822776-7534@assetmemo.bio
DTSTAMP:20261121T005619Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Vyvgart (Efgartigimod Alfa): Phase 2 readout est. (NCT07822776)
DESCRIPTION:Vyvgart (Efgartigimod Alfa)\, phase 2.\nStudy: Efgartigimod in 
 Anti-NMDA Receptor Encephalitis.\nEstimated primary completion: 31 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/efgartigimod-
 alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07822776
URL:https://assetmemo.bio/drug/efgartigimod-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011589-7534@assetmemo.bio
DTSTAMP:20261121T005619Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Vyvgart (Efgartigimod Alfa): Phase 1/2 readout est. (NCT07011589)
DESCRIPTION:Vyvgart (Efgartigimod Alfa)\, phase 1/2.\nStudy: Targeting Coll
 agen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)\nE
 stimated primary completion: January 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/efgartigimod-alfa#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07011589
URL:https://assetmemo.bio/drug/efgartigimod-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
